ANTIHYPERKINESIS AGENTS PA SUMMARY

| PREFERRED | Amphetamine-Dextroamphetamine, Amphetamine Salt combo, Dextroamphetamine Sulfate, Focalin/XR, Metadate CD/ER, Methylin Chew Tabs, Methylin/ER, Methylphenidate SA/SR/ER (including generic Concerta tablets, excluding generic Ritalin LA and generic Metadate CD), Vyvanse |
| NON-PREFERRED | Branded versions of generic equivalents, Adderall, Adderall XR, Amphetamine Salt Combo Extended-Release, Concerta (brand), Daytrana, Desoxyn, Dextedrine caps/tabs, Dexamphetamine, Intuniv, Kapvay/Kapvay Therapy Pack, Methamphetamine, Methylphenidate oral solution, Methylin oral solution, Methylphenidate CD extended-release (generic for Metadate CD), Modafinil (generic), Nuvigil, Procentra, Provigil (brand), Quillivant XR, Straterra, Ritalin, Ritalin LA (brand or generic), Ritalin SR |

LENGTH OF AUTHORIZATION: 1 YEAR

NOTE: All preferred and non-preferred agents will be subject to the DCH clinical PA criteria review for members 21 years of age and older. Adderall XR (brand or generic), Daytrana, Desoxyn (brand or generic), Dexamphetamine, Intuniv, Kapvay, Kapvay Therapy Pack, Methylin oral solution (brand or generic), Methylphenidate CD extended-release (generic), Nuvigil, Procentra, Quillivant XR, Ritalin LA (brand or generic), and Straterra are non-preferred agents that require prior authorization for members of all ages. If a PA is approved for Amphetamine Salt Combo ER, Methamphetamine, brand-name Methylphenidate oral solution, Modafinil, brand-name Concerta, or brand-name Ritalin LA the approval will be for the products, Adderall XR, Desoxyn, generic methylphenidate oral solution, Provigil, generic methylphenidate SA, or generic Ritalin LA, respectively.

PA CRITERIA:
For all agents for members 21 years of age and older (except Adderall XR [brand or generic], Daytrana, Desoxyn [brand or generic], Dexamphetamine, Intuniv, Kapvay, Kapvay Therapy Pack, Methylin oral solution [brand or generic], Methylphenidate CD extended-release [generic], Nuvigil, Provigil [brand or generic], Procentra, Quillivant XR, Ritalin LA [brand or generic], and Straterra)

- Approvable diagnoses are as follows:
  - Narcolepsy
  - Attention Deficit Disorder (ADD) or Attention Deficit Hyperactivity Disorder (ADHD)

For Desoxyn (brand or generic), Adderall XR (brand or generic), and Ritalin LA (brand or generic)

- Member must have initiated therapy with at least 1 agent in at least 2 of the following groups in the past 12 months: 1. amphetamine salt combinations, Vyvanse 2. Concerta, methylphenidate HCL, Metadate CD, Methylin, Methylin

Revised 3/21/2013

OR
- Submit documentation of ineffectiveness, allergies, contraindications, drug-drug interactions, or show a history of intolerable side effects to at least 1 medication in at least 2 of the groups listed above.

For Intuniv, Kapvay, and Kapvay Therapy Pack
- Requests are approvable for members aged 6 to 17 years old. Members must have a diagnosis of ADD or ADHD and a personal or family history of substance abuse. Alternatively, patients must meet Desoxyn criteria above.

For Provigil (brand or generic) and Nuvigil
- Diagnosis of narcolepsy, shift work sleep disorder, and obstructive sleep apnea/hypo-apnea syndrome (with CPAP machine use) are approvable indications. Patients with narcolepsy must be on CPAP treatment. Otherwise, patient must meet Desoxyn criteria listed above. Provigil is approvable under the above conditions for members 16 years of age or older. Nuvigil is approvable under the above conditions for members 17 years of age or older.

For Strattera
- Strattera requests are approvable for diagnoses of ADD or ADHD for members with a personal or family history of substance abuse. Alternatively, patients must meet Desoxyn criteria above.

For Daytrana
- Member must be aged 6-17 years with a diagnosis of ADD or ADHD
  AND
- Member must be unable to swallow oral dosage forms of medication
  OR
- Member must have tried and failed at least 1 agent in drug group 2 or 3 and 1 agent in group 1 or 4 in the Desoxyn criteria above.

For Procentra
- Member must have a diagnosis of ADD or ADHD and be unable to swallow solid oral dosage forms of medication (ex. tablets, capsules).

For Methylin oral solution (brand) or Methylphenidate oral solution (generic)
- Member must have a diagnosis of ADD or ADHD or narcolepsy and be unable to swallow solid oral dosage forms (ex. tablets, capsules). If brand-name Methylin oral solution is prescribed, provider must submit a written letter of medical necessity stating the reason(s) that the generic product (methylphenidate SA or generic methylphenidate oral solution) is not appropriate for the member.
For Quillivant XR

- Member must have a diagnosis of ADD or ADHD and be unable to swallow solid oral dosage forms of medication (ex. tablets, capsules) or sprinkle the preferred products, Focalin XR or Metadate CD, on applesauce and swallow intact.

For Generic Dexmethylphenidate or Generic Methylphenidate CD extended-release

- Submit a written letter of medical necessity stating the reason(s) that the brand name product (Focalin or Metadate CD) is not appropriate for the member.

QLL CRITERIA:

For Vyvanse

- An authorization to exceed the QLL may be granted if the member has not achieved an adequate response with FDA-approved maximum dosing (70mg/day) if the member will be monitored for effectiveness and adverse events with the higher dosage.

EXCEPTIONS:

- Exceptions to these conditions of coverage are considered through the prior authorization process.
- The Prior Authorization process may be initiated by calling Catamaran at 1-866-525-5827.

PA and APPEAL PROCESS:

- For online access to the PA process please go to www.mmis.georgia.gov/portal, highlight the pharmacy link on the top right side of the page, and click on “prior approval process”.

QUANTITY LEVEL LIMITATIONS:

- For online access to the current Quantity Level Limits please go to www.mmis.georgia.gov/portal, highlight Provider Information and click on Provider Manuals. Scroll to the page with Pharmacy Services Part II and select that manual.

Revised 3/21/2013